Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

Jason A. Chesney, M.D., Ph.D.

  • Professor of Medicine, Pharmacology and Toxicology, Biochemistry and Molecular Biology
  • Chief, Division of Medical Oncology and Hematology
  • Director, James Graham Brown Cancer Center
  • Medical Director, Clinical Trials Office, James Graham Brown Cancer Center
  • Associate Director, Translational Research Program, James Graham Brown Cancer Center
  • James Graham Brown Foundation Chair
UofL James Graham Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202

502-852-2522 - Academic Office
502-562-4370 - Patient Appointments


Clinical Expertise
Metastatic Melanoma; Refractory Solid Tumors; Clinical Trial Testing of Immunotherapeutics; Development of Anti-Metabolites as Targeted Chemotherapies

 

Education and Training

  • Medical School: University of Minnesota
  • Residency: Memorial Sloan-Kettering Cancer Center
  • Fellowship: Cornell University Medical College
  • Ph.D.: University of Minnesota

 

Featured Publications

  • Chesney J, Imbert-Fernandez Y, Telang S, Baum M, Ranjan S, Fraig M, Batty N. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000444. [Epub ahead of print] PubMed PMID: 29561296.
  • Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399. PubMed PMID: 29176501.
  • Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25. PubMed PMID: 28841387; PubMed Central PMCID: PMC5791828.
  • Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2017 Oct 5:JCO2017737379. doi: 10.1200/JCO.2017.73.7379. [Epub ahead of print] PubMed PMID: 28981385.
  • Chesney JA, Mitchell RA, Yaddanapudi K. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. J Leukoc Biol. 2017 Sep;102(3):727-740. doi: 10.1189/jlb.5VMR1116-458RRR. Epub 2017 May 25. Review. PubMed PMID: 28546500.
  • Yusuf MB, Amsbaugh MJ, Burton E, Chesney J, Woo S. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. World Neurosurg. 2017 Apr;100:632-640.e4. doi: 10.1016/j.wneu.2017.01.101. Epub 2017 Feb 4. PubMed PMID: 28179176.
  • Yalcin A, Solakoglu TH, Ozcan SC, Guzel S, Peker S, Celikler S, Balaban BD, Sevinc E, Gurpinar Y, Chesney JA. 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is required for transforming growth factor β1-enhanced invasion of Panc1 cells in vitro. Biochem Biophys Res Commun. 2017 Mar 11;484(3):687-693. doi: 10.1016/j.bbrc.2017.01.178. Epub 2017 Feb 1. PubMed PMID: 28161638.
  • O'Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, Chesney J, Clem BF. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res Treat. 2016 Nov;160(1):29-40. Epub 2016 Sep 9. PubMed PMID: 27613609.
  • Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9. PubMed PMID: 27622997; PubMed Central PMCID: PMC5630525.
  • Chesney J, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356. Erratum in: Autophagy. 2016;12(2):443. Selliez, Iban [corrected to Seiliez, Iban]. PubMed PMID: 26799652; PubMed Central PMCID: PMC4835977.